• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Spain·Healthcare·CBAV.MC
Share

Clinica Baviera, S.A. Stocks

€ 58.8Last Updated 25.08.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

€ 1.10B

€ 58.8
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. Operating around 90 sites, the company's geographical footprint extends across Spain, Germany, Austria, and Italy. The corporate headquarters are located in Madrid, Spain.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.08.2026 20:40

At least 95 people have died, and hundreds are missing following floods in China and Nepal

26.08.2026 20:03

Microsoft, Amazon, and Google May Host a Chinese AI Model in Their Clouds — Media Reports

26.08.2026 19:32

Meta Will Pay Up to $16.7 Billion to Settle a Lawsuit Over the Harmful Effects of Social Media on Children

26.08.2026 19:00

Bill Gates called for securing jobs for people to protect the labor market from AI

26.08.2026 18:30

Iran announced that it had reached an agreement with Oman on the "sharing of revenues" from the Strait of Hormuz

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026